Investors - Press Releases
Tabula Rasa HealthCare Named Principal Distributor of the BioIntelliSense BioSticker™ for Programs of All-Inclusive Care for the Elderly (PACE)
The BioIntelliSense DaaS platform can be applied to a wide range of clinical use cases, including monitoring for the key symptoms associated with COVID-191.
“BioSticker remote monitoring devices will add an additional layer of patient safety to MedWise™ and to the other software solutions we currently offer,” said TRHC Co-founder, Chairman and CEO
BioSticker device data will populate TRHC’s unique medication safety platforms that identifiy accumulative multi-drug interactions and facilitate collaborative management of medications. TRHC’s board-certified pharmacists will access BioSticker device data to alert client clinicians to timely medication-related issues, enabling proactive intervention for safer medication use.
“As TRHC serves a variety of healthcare clients, including the majority of PACE organizations in
PACE is a federal program providing comprehensive medical and social services to individuals 55 and older who are nursing-home eligible. The goal of PACE is to keep participants living in their own communities and to provide quality medical care. Currently, 131 PACE programs operate 263 PACE centers in 31 states, serving over 53,899 participants.
1 as described by the
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures minute-to-minute vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA 510(k)-cleared BioStickerÔ device, in combination with advanced predictive analytics, is uniquely designed to screen for adverse conditions and detect trends to enable the next generation of personalized, proactive care.
For more information on how BioIntelliSense is redefining remote patient monitoring through advanced medical-grade and cost-effective services, please contact us at email@example.com or visit our website at BioIntelliSense.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the
TRHC Media Relations
Source: Tabula Rasa HealthCare, Inc.